In preclinical investigations, the intervention of the PI3K/AKT pathway has shown the advantages in improving chronic inflammation in COPD, suggesting that the PI3K/AKT pathway may be the hopeful treating target [94, 95]. This evidence concerns the gene AKT1 and chronic obstructive pulmonary disease.